PubMed HealthSearch

PubMed · 42724511

Investigating the mechanisms of PhIP-induced colorectal cancer through network toxicology, machine learning, and molecular dynamics simulation.

Abstract

BACKGROUND: Over the past few years, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)- a compound from grilled or processed meats-has emerged as a major player in cancer development, especially colorectal cancer (CRC). This work dives into its potential links to CRC and uncovers the key genes that bridge this connection. METHODS: We tapped into various databases to pinpoint target genes tied to PhIP and CRC, then ran protein-protein interaction (PPI) analyses for visualization. Next, we explored underlying mechanisms through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. To nail down predictions, we tested 107 machine learning pipelines and picked the best one, validating its accuracy and the core genes' prognostic value across datasets. Next, molecular docking and dynamics simulations probed the interactions between these genes and PhIP. Finally, cell proliferation was assessed using Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) assays, and polymerase chain reaction (PCR) was performed to validate the expression levels of the hub genes. RESULTS: Our analysis identified 39 overlapping genes, from which a machine learning model (glmBoost + Enet) identified six candidate targets: CDK4, CEBPB, COMT, SOX9, TIMP1, and TOP2A. To prioritize these, a hierarchical screening framework was applied. Molecular docking and dynamics simulations identified CDK4, COMT, and TIMP1 as the most stable interactors with PhIP. Functional assays confirmed that PhIP treatment significantly enhanced the proliferation of CRC cells. Crucially, quantitative PCR (qPCR) validation in multiple CRC cell lines identified TIMP1 as the primary target, showing the most consistent and significant upregulation upon PhIP exposure. CONCLUSIONS: In essence, these genes drive PhIP is role in CRC, offering novel insights into its molecular pathways. This could reshape how we tackle food-related pollutants, paving the way for better prevention and targeted therapies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yuqi Gao, Qian Ye, Yunhuan Zhen, Yan Wang, Yi Wang, Yuping Zeng, Xiaoqin Liu, Xiaoru Zhou, Weiwei Chen. 2026-07-23. Investigating the mechanisms of PhIP-induced colorectal cancer through network toxicology, machine learning, and molecular dynamics simulation.. https://doi.org/10.21037/tcr-2026-0832

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection.

BACKGROUND: Colorectal cancer (CRC) is a common malignancy associated with genetic and epigenetic alterations. Several methylation biomarkers have been investigated for non-invasive CRC detection; however, their reported performance varies across clinical settings, and the detection of early-stage or precancerous disease and discrimination from non-malignant colorectal conditions remain challenging. This exploratory study aimed to identify reproducible CRC-associated plasma cell-free DNA (cfDNA) methylation regions and to develop and preliminarily evaluate diagnostic prediction model for distinguishing CRC from healthy controls and benign samples. METHODS: Public CRC tissue methylation datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed to identify reproducible CRC-associated methylation alterations. Plasma cfDNA methylation was profiled using methyl-CpG-binding-domain enrichment followed by paired-end sequencing in patients with CRC, patients with colorectal polyps, and healthy controls. After quality-control filtering, 30 CRC and healthy-control samples were randomly allocated at the participant level in a 7:3 ratio to a development set comprising 10 patients with CRC and 11 healthy controls and a held-out test set comprising 4 patients with CRC and 5 healthy controls. Hypermethylated regions were selected using least absolute shrinkage and selection operator (LASSO) logistic regression. The 12-region model was evaluated in the held-out test set and subsequently applied to 10 colorectal polyp samples without refitting or recalibration. RESULTS: Tissue methylation analysis identified reproducible CRC-associated alterations across independent datasets. In the plasma development set, 707 differentially methylated regions (DMRs) were identified between CRC and healthy-control samples, including 324 hypermethylated and 383 hypomethylated regions. LASSO regression selected a 12-region hypermethylation signature. In the held-out test set, the model achieved an area under the curve (AUC) of 0.85 [95% confidence interval (CI): 0.579-1.000]. At the development-set-derived threshold, sensitivity was 75.0% (3/4), specificity was 60.0% (3/5), and accuracy was 66.7% (6/9). When the original model was applied to colorectal polyp samples, model scores were significantly higher in both CRC and polyp samples than in healthy controls, while CRC samples showed a tendency toward higher scores than polyp samples. CONCLUSIONS: This exploratory study identified a 12-region plasma cfDNA hypermethylation signature associated with CRC and developed a LASSO-based diagnostic prediction model that showed preliminary discrimination between CRC and healthy controls in a small held-out test set. By integrating tissue methylation evidence with plasma cfDNA profiling, this study expands the repertoire of candidate region-level methylation markers for blood-based CRC detection.

Colorectal cancer (CRC)

Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer.

BACKGROUND: Metabolic cell death (MCD) modulates colorectal cancer (CRC) progression, yet its prognostic value remains unexplored. We aimed to build an MCD-centred gene signature for outcome prediction and precision therapy. METHODS: Transcriptomes of 1,174 CRC patients were integrated. Weighted gene co-expression network analysis, differential expressions and least absolute shrinkage and selection operator (LASSO) + random survival forest were successively applied to derive a three-gene (CDKN2A/MPC1/AHCY) risk model. Functional, immune-infiltration, drug-sensitivity and genomic analyses were performed, followed by validation in fresh clinical specimens and cell lines. RESULTS: Integrative metabolic-death transcriptomics identified CDKN2A, MPC1 and AHCY as the hub drivers of CRC. Their three-gene signature robustly stratified patients into high- and low-risk subsets [3-year area under the curve (AUC) 0.83-0.85, P<0.001]. High-risk tumors were enriched for extracellular matrix (ECM)-receptor-interaction pathways, displayed abundant myeloid-derived suppressor cell (MDSC) infiltration and were more vulnerable to AZD8186, AZ960 and JAK inhibitors. Guided by these in-silico findings, we functionally confirmed that CDKN2A silencing markedly repressed proliferation, invasion and migration of SW480/HCT116 cells and potentiated cuproptosis via up-regulation of lipoylated DLAT/DLST and CTR1. CONCLUSIONS: We report the first MCD-derived prognostic platform for CRC that simultaneously predicts survival and therapeutic response. Targeting CDKN2A-enhanced cuproptosis represents a promising metabolic-precision strategy for high-risk patients.

Colorectal cancer (CRC)